Wrap Text
Notification of transactions by PDMR and persons closely associated with
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
(“Mediclinic”, the “Company” or the “Group”)
6 June 2017
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Vesting of awards under the Company's Forfeitable Share Plan
The awards of ordinary shares in Mediclinic (the “Shares”) set out in the table below, granted on 31
July 2014, vested under the Company’s Forfeitable Share Plan on 31 May 2017.
Name Director/ Number of Number of Number of
PDMR Shares Shares sold at Shares
vested ZAR 130.44 retained(1)
per share
Danie Meintjes Director 49,423 0 49,423
Gert Hattingh PDMR 14,734 0 14,734
Koert Pretorius PDMR 19,806 19,806 0
David Hadley PDMR 9,778 9,778 0
Dr Ole Wiesinger(1) PDMR 17,506 0 17,506
Dr Ronnie van der Merwe PDMR 16,507 16,507 0
1. Dr Wiesinger was granted a conditional right to 17,506 Shares under the Country Schedule to the Forfeitable
Share Plan on 31 July 2014. On 1 June 2017, Dr Wiesinger elected to receive the award in Shares, which he
received on 5 June 2017.
The following notification made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation relates to the Company’s Forfeitable Share Plan.
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Daniël Petrus Meintjes
2. Reason for the notification
a) Position / status Chief Executive Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting of award over 49,423 ordinary shares awarded under the
transaction Company’s Forfeitable Share Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 49,423
d) Aggregated
information
Aggregated volume 49,423
Price Nil cost
e) Date of the 1 June 2017
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Gert C Hattingh
2. Reason for the notification
a) Position / status Chief Corporate Services Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting of award over 14,734 ordinary shares awarded under the
transaction Company’s Forfeitable Share Plan
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 14,734
d) Aggregated
information
Aggregated volume 14,734
Price Nil cost
e) Date of the 1 June 2017
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Koert Hendrik S Pretorius
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Southern Africa
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the 1. Vesting of award over 19,806 ordinary shares awarded under
transaction the Company’s Forfeitable Share Plan
2. Sale of 19,806 ordinary shares.
c) Price(s) and
volume(s) Price(s) Volume(s)
1. Nil cost 1. 19,806
2. ZAR 130.44 2. 19,806
d) Aggregated
information
Aggregated volume 1. 19,806
2. 19,806
Price 1. Nil cost
2. ZAR 130.44
e) Date of the 1 June 2017
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name David J Hadley
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Middle East
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the 1. Vesting of award over 9,778 ordinary shares awarded under the
transaction Company’s Forfeitable Share Plan
2. Sale of 9,778 ordinary shares.
c) Price(s) and
volume(s) Price(s) Volume(s)
1. Nil cost 1. 9,778
2. ZAR 130.44 2. 9,778
d) Aggregated
information
Aggregated volume 1. 9,778
2. 9,778
Price 1. Nil cost
2. ZAR 130.44
e) Date of the 1 June 2017
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Thorsten Ole Wiesinger
2. Reason for the notification
a) Position / status Chief Executive Officer – Hirslanden
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting of conditional right to 17,506 Shares under the Country Schedule
transaction to the Forfeitable Share Plan on 31 July 2014
c) Price(s) and
volume(s) Price(s) Volume(s)
Nil cost 17,506
d) Aggregated
information
Aggregated volume 17,506
Price Nil cost
e) Date of the 5 June 2017
transaction
f) Place of the Johannesburg Stock Exchange
transaction
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Carel A van der Merwe
2. Reason for the notification
a) Position / status Chief Clinical Officer of the Company
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform,
auctioneer or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have
been conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the 1. Vesting of award over 16,507 ordinary shares awarded under
transaction the Company’s Forfeitable Share Plan
2. Sale of 16,507 ordinary shares.
c) Price(s) and
volume(s) Price(s) Volume(s)
1. Nil cost 1. 16,507
2. ZAR 130.44 2. 16,507
d) Aggregated
information
Aggregated volume 1. 16,507
2. 16,507
Price 1. Nil cost
2. ZAR 130.44
e) Date of the 1 June 2017
transaction
f) Place of the Johannesburg Stock Exchange
transaction
About Mediclinic International plc
Mediclinic is an international private healthcare group with operating platforms in Southern Africa (South
Africa and Namibia), Switzerland and the United Arab Emirates. Its core purpose is to enhance the
quality of life of patients by providing acute care, specialist-orientated, multi-disciplinary healthcare
services. Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a LSE listed and UK-
based private healthcare group.
Mediclinic comprises 74 hospitals and 37 clinics. Mediclinic Southern Africa operates 49 hospitals and
2 day clinics throughout South Africa and 3 hospitals in Namibia with more than 8 000 inpatient beds in
total; Hirslanden operates 16 private acute care facilities and 4 clinics in Switzerland with more than 1
600 inpatient beds; and Mediclinic Middle East operates 6 hospitals and 31 clinics with more than 700
inpatient beds in the United Arab Emirates.
During February 2016, the combination of the Company (previously named Al Noor Hospitals Group
plc), with operations mainly in Abu Dhabi in the United Arab Emirates, and Mediclinic International
Limited was completed. Mediclinic International Limited was a South African based international private
healthcare group founded in 1983 and listed on the JSE, the South African stock exchange, since 1986,
with operations in South Africa, Namibia, Switzerland and the United Arab Emirates (mainly in Dubai).
The combination resulted in the renaming of the enlarged group to Mediclinic International plc.
Mediclinic has a primary listing on the Main Market of the LSE, with secondary listings on the JSE in
South Africa and the NSX in Namibia.
For further information, please contact:
Capita Company Secretarial Services Limited
Victoria Dalby
+44 (0)207 954 9600
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Brett Pollard/Debbie Scott (UK)
+44 (0)20 3727 1000
Frank Ford (South Africa)
+27 (0)21 487 9000
Registered address: 1st Floor, 40 Dukes Place, London, EC3A 7NH, United Kingdom
Website: www.mediclinic.com
Corporate broker: Morgan Stanley & Co International plc
JSE sponsor: RAND MERCHANT BANK (A division of FirstRand Bank Limited)
NSX sponsor: Simonis Storm Securities (Pty) Ltd
Date: 07/06/2017 07:45:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
